# Boeing Co: financial statements, quarterly

BA · NYSE · CIK 12927 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ba.md) · [Financials](/companies/ba/financials.md) · [Filings](/companies/ba/filings.md) · [Insiders](/companies/ba/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ba/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [18.1](/filings/0000012927-24-000082.md) | [22.0 d](/filings/0001628280-26-004357.md) | [16.6](/filings/0000012927-25-000031.md) | [16.9](/filings/0000012927-25-000062.md) | [17.8](/filings/0001628280-25-047023.md) | [15.2 d](/filings/0001628280-26-004357.md) | [19.5](/filings/0001628280-26-026458.md) | [22.7](/filings/0001628280-26-050038.md) | [23.3](/filings/0001628280-25-047023.md) | [23.9 d](/filings/0001628280-26-004357.md) | [22.2](/filings/0001628280-26-026458.md) | [24.6](/filings/0001628280-26-050038.md) |
| Cost of revenue | $bn | [16.9](/filings/0000012927-24-000082.md) | [19.3 d](/filings/0001628280-26-004357.md) | [14.7](/filings/0000012927-25-000031.md) | [15.6](/filings/0000012927-25-000062.md) | [21.3](/filings/0001628280-25-047023.md) | [16.8 d](/filings/0001628280-26-004357.md) | [17.1](/filings/0001628280-26-026458.md) | [20.3](/filings/0001628280-26-050038.md) | [25.6](/filings/0001628280-25-047023.md) | [22.1 d](/filings/0001628280-26-004357.md) | [19.7](/filings/0001628280-26-026458.md) | [22.1](/filings/0001628280-26-050038.md) |
| Gross profit | $bn | [1.2](/filings/0000012927-24-000082.md) | [2.7 d](/filings/0001628280-26-004357.md) | [1.9](/filings/0000012927-25-000031.md) | [1.2](/filings/0000012927-25-000062.md) | [(3.5)](/filings/0001628280-25-047023.md) | [(1.6) d](/filings/0001628280-26-004357.md) | [2.4](/filings/0001628280-26-026458.md) | [2.4](/filings/0001628280-26-050038.md) | [(2.4)](/filings/0001628280-25-047023.md) | [1.8 d](/filings/0001628280-26-004357.md) | [2.5](/filings/0001628280-26-026458.md) | [2.4](/filings/0001628280-26-050038.md) |
| Research and development | $bn | [1.0](/filings/0000012927-24-000082.md) | [0.9 d](/filings/0001628280-26-004357.md) | [0.9](/filings/0000012927-25-000031.md) | [1.0](/filings/0000012927-25-000062.md) | [1.2](/filings/0001628280-25-047023.md) | [0.8 d](/filings/0001628280-26-004357.md) | [0.8](/filings/0001628280-26-026458.md) | [0.9](/filings/0001628280-26-050038.md) | [0.9](/filings/0001628280-25-047023.md) | [1.0 d](/filings/0001628280-26-004357.md) | [0.9](/filings/0001628280-26-026458.md) | [0.9](/filings/0001628280-26-050038.md) |
| Operating income | $bn | [(0.8)](/filings/0000012927-24-000082.md) | [0.3 d](/filings/0001628280-26-004357.md) | [(0.1)](/filings/0000012927-25-000031.md) | [(1.1)](/filings/0000012927-25-000062.md) | [(5.8)](/filings/0001628280-25-047023.md) | [(3.8) d](/filings/0001628280-26-004357.md) | [0.5](/filings/0001628280-26-026458.md) | [(0.2)](/filings/0001628280-26-050038.md) | [(4.8)](/filings/0001628280-25-047023.md) | [8.8 d](/filings/0001628280-26-004357.md) | [0.4](/filings/0001628280-26-026458.md) | [0.2](/filings/0001628280-26-050038.md) |
| Income tax | $bn | [0.5](/filings/0000012927-24-000082.md) | [0.0 d](/filings/0001628280-26-004357.md) | [(0.0)](/filings/0000012927-25-000031.md) | [(0.1)](/filings/0000012927-25-000062.md) | [(0.1)](/filings/0001628280-25-047023.md) | [(0.2) d](/filings/0001628280-26-004357.md) | [0.1](/filings/0001628280-26-026458.md) | [0.1](/filings/0001628280-26-050038.md) | [0.1](/filings/0001628280-25-047023.md) | [0.1 d](/filings/0001628280-26-004357.md) | [0.0](/filings/0001628280-26-026458.md) | [0.1](/filings/0001628280-26-050038.md) |
| Net income | $bn | [(1.6)](/filings/0000012927-24-000082.md) | [(0.0) d](/filings/0001628280-26-004357.md) | [(0.3)](/filings/0000012927-25-000031.md) | [(1.4)](/filings/0000012927-25-000062.md) | [(6.2)](/filings/0001628280-25-047023.md) | [(3.9) d](/filings/0001628280-26-004357.md) | [(0.0)](/filings/0001628280-26-026458.md) | [(0.6)](/filings/0001628280-26-050038.md) | [(5.3)](/filings/0001628280-25-047023.md) | [8.2 d](/filings/0001628280-26-004357.md) | [(0.0)](/filings/0001628280-26-026458.md) | [(0.4)](/filings/0001628280-26-050038.md) |
| Diluted EPS | $ per share | [(2.70)](/filings/0000012927-24-000082.md) | not reported | [(0.56)](/filings/0000012927-25-000031.md) | [(2.33)](/filings/0000012927-25-000062.md) | [(9.97)](/filings/0001628280-25-047023.md) | not reported | [(0.16)](/filings/0001628280-26-026458.md) | [(0.92)](/filings/0001628280-26-050038.md) | [(7.14)](/filings/0001628280-25-047023.md) | not reported | [(0.11)](/filings/0001628280-26-026458.md) | [(0.67)](/filings/0001628280-26-050038.md) |
| Basic EPS | $ per share | [(2.70)](/filings/0000012927-24-000082.md) | not reported | [(0.56)](/filings/0000012927-25-000031.md) | [(2.33)](/filings/0000012927-25-000062.md) | [(9.97)](/filings/0001628280-25-047023.md) | not reported | [(0.16)](/filings/0001628280-26-026458.md) | [(0.92)](/filings/0001628280-26-050038.md) | [(7.14)](/filings/0001628280-25-047023.md) | not reported | [(0.11)](/filings/0001628280-26-026458.md) | [(0.67)](/filings/0001628280-26-050038.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [6.8](/filings/0000012927-24-000082.md) | [12.7](/filings/0001628280-26-004357.md) | [6.9](/filings/0000012927-25-000031.md) | [10.9](/filings/0000012927-25-000062.md) | [10.0](/filings/0001628280-25-047023.md) | [13.8](/filings/0001628280-26-004357.md) | [10.1](/filings/0001628280-26-026458.md) | [7.1](/filings/0001628280-26-050038.md) | [6.2](/filings/0001628280-25-047023.md) | [10.9](/filings/0001628280-26-050038.md) | [9.4](/filings/0001628280-26-026458.md) | [7.2](/filings/0001628280-26-050038.md) |
| Current assets | $bn | [107](/filings/0000012927-23-000062.md) | [109](/filings/0000012927-25-000015.md) | [107](/filings/0000012927-24-000025.md) | [114](/filings/0000012927-24-000055.md) | [109](/filings/0000012927-24-000082.md) | [128](/filings/0001628280-26-004357.md) | [128](/filings/0000012927-25-000031.md) | [127](/filings/0000012927-25-000062.md) | [122](/filings/0001628280-25-047023.md) | [128](/filings/0001628280-26-050038.md) | [124](/filings/0001628280-26-026458.md) | [125](/filings/0001628280-26-050038.md) |
| Total assets | $bn | [134](/filings/0000012927-23-000062.md) | [137](/filings/0000012927-25-000015.md) | [134](/filings/0000012927-24-000025.md) | [143](/filings/0000012927-24-000055.md) | [138](/filings/0000012927-24-000082.md) | [156](/filings/0001628280-26-004357.md) | [156](/filings/0000012927-25-000031.md) | [155](/filings/0000012927-25-000062.md) | [150](/filings/0001628280-25-047023.md) | [168](/filings/0001628280-26-050038.md) | [165](/filings/0001628280-26-026458.md) | [166](/filings/0001628280-26-050038.md) |
| Current liabilities | $bn | [93.1](/filings/0000012927-23-000062.md) | [95.8](/filings/0000012927-25-000015.md) | [93.3](/filings/0000012927-24-000025.md) | [96.6](/filings/0000012927-24-000055.md) | [97.3](/filings/0000012927-24-000082.md) | [97.1](/filings/0001628280-26-004357.md) | [104](/filings/0000012927-25-000031.md) | [103](/filings/0000012927-25-000062.md) | [103](/filings/0001628280-25-047023.md) | [108](/filings/0001628280-26-050038.md) | [106](/filings/0001628280-26-026458.md) | [110](/filings/0001628280-26-050038.md) |
| Total liabilities | $bn | [151](/filings/0000012927-23-000062.md) | [154](/filings/0000012927-25-000015.md) | [152](/filings/0000012927-24-000025.md) | [161](/filings/0000012927-24-000055.md) | [161](/filings/0000012927-24-000082.md) | [160](/filings/0001628280-26-004357.md) | [160](/filings/0000012927-25-000031.md) | [158](/filings/0000012927-25-000062.md) | [158](/filings/0001628280-25-047023.md) | [163](/filings/0001628280-26-050038.md) | [159](/filings/0001628280-26-026458.md) | [160](/filings/0001628280-26-050038.md) |
| Long-term debt | $bn | [52.0](/filings/0000012927-23-000062.md) | [52.1](/filings/0000012927-25-000015.md) | [47.7](/filings/0000012927-24-000025.md) | [57.7](/filings/0000012927-24-000055.md) | [57.4](/filings/0000012927-24-000082.md) | [53.6](/filings/0001628280-26-004357.md) | [53.4](/filings/0000012927-25-000031.md) | [53.1](/filings/0000012927-25-000062.md) | [53.2](/filings/0001628280-25-047023.md) | [53.8](/filings/0001628280-26-050038.md) | [47.0](/filings/0001628280-26-026458.md) | [45.6](/filings/0001628280-26-050038.md) |
| Current portion of debt | $bn | [4.9](/filings/0000012927-23-000062.md) | [5.2](/filings/0000012927-25-000015.md) | [1.1](/filings/0000012927-24-000025.md) | [4.8](/filings/0000012927-24-000055.md) | [4.5](/filings/0000012927-24-000082.md) | [1.3](/filings/0001628280-26-004357.md) | [7.9](/filings/0000012927-25-000031.md) | [8.7](/filings/0000012927-25-000062.md) | [8.7](/filings/0001628280-25-047023.md) | [8.5](/filings/0001628280-26-050038.md) | [2.9](/filings/0001628280-26-026458.md) | [4.6](/filings/0001628280-26-050038.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [(16.7)](/filings/0000012927-23-000062.md) | [(17.2)](/filings/0000012927-25-000015.md) | [(17.0)](/filings/0000012927-24-000025.md) | [(18.0)](/filings/0000012927-24-000055.md) | [(23.6)](/filings/0000012927-24-000082.md) | [(3.9)](/filings/0001628280-26-004357.md) | [(3.3)](/filings/0000012927-25-000031.md) | [(3.3)](/filings/0000012927-25-000062.md) | [(8.3)](/filings/0001628280-25-047023.md) | [5.5](/filings/0001628280-26-050038.md) | [6.0](/filings/0001628280-26-026458.md) | [6.1](/filings/0001628280-26-050038.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [22.0 d](/filings/0000012927-24-000082.md) | [3,381 d](/filings/0001628280-26-004357.md) | [(3,362)](/filings/0000012927-25-000031.md) | [(3,923) d](/filings/0000012927-25-000062.md) | [(1,345) d](/filings/0001628280-25-047023.md) | [(3,450) d](/filings/0001628280-26-004357.md) | [(1,616)](/filings/0001628280-26-026458.md) | [227 d](/filings/0001628280-26-050038.md) | [1,123 d](/filings/0001628280-25-047023.md) | [1,331 d](/filings/0001628280-26-004357.md) | [(179)](/filings/0001628280-26-026458.md) | [1,364 d](/filings/0001628280-26-050038.md) |
| Capital expenditure | $m | [332 d](/filings/0000012927-24-000082.md) | [431 d](/filings/0001628280-26-004357.md) | [567](/filings/0000012927-25-000031.md) | [404 d](/filings/0000012927-25-000062.md) | [611 d](/filings/0001628280-25-047023.md) | [648 d](/filings/0001628280-26-004357.md) | [674](/filings/0001628280-26-026458.md) | [427 d](/filings/0001628280-26-050038.md) | [885 d](/filings/0001628280-25-047023.md) | [956 d](/filings/0001628280-26-004357.md) | [1,275](/filings/0001628280-26-026458.md) | [733 d](/filings/0001628280-26-050038.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | [72.0](/filings/0001628280-26-026458.md) | [86.0](/filings/0001628280-26-050038.md) | [86.0](/filings/0001628280-25-047023.md) | [87.0 d](/filings/0001628280-26-004357.md) | [86.0](/filings/0001628280-26-026458.md) | [86.0](/filings/0001628280-26-050038.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [596](/filings/0000012927-23-000062.md) | [602](/filings/0000012927-24-000025.md) | [605](/filings/0000012927-24-000055.md) | [607](/filings/0000012927-24-000082.md) | [613](/filings/0000012927-25-000031.md) | [616](/filings/0000012927-25-000062.md) | [619](/filings/0001628280-25-047023.md) | [753](/filings/0001628280-26-026458.md) | [757](/filings/0001628280-26-050038.md) | [760](/filings/0001628280-25-047023.md) | [788](/filings/0001628280-26-026458.md) | [791](/filings/0001628280-26-050038.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 790,370,020 at 2026-07-21, from the cover of the [10-Q filed 2026-07-28](/filings/0001628280-26-050038.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.